DOP2018000034A - Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas - Google Patents

Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas

Info

Publication number
DOP2018000034A
DOP2018000034A DO2018000034A DO2018000034A DOP2018000034A DO P2018000034 A DOP2018000034 A DO P2018000034A DO 2018000034 A DO2018000034 A DO 2018000034A DO 2018000034 A DO2018000034 A DO 2018000034A DO P2018000034 A DOP2018000034 A DO P2018000034A
Authority
DO
Dominican Republic
Prior art keywords
combinations
antibody
same
modulator
tlr4 modulator
Prior art date
Application number
DO2018000034A
Other languages
English (en)
Inventor
Jonh Francis Christopher
Gao Hua-Xin
YANAMANDRA Niranjan
Li Yufeng
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of DOP2018000034A publication Critical patent/DOP2018000034A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046Stomach, Intestines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen en este documento combinaciones de un modulador de OX40 y un modulador de TLR4, sus composiciones farmacéuticas, sus usos y métodos de tratamiento que comprenden administrar dicha combinación, incluyendo sus usos en el cáncer.
DO2018000034A 2015-08-06 2018-02-05 Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas DOP2018000034A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562201828P 2015-08-06 2015-08-06
US201562247488P 2015-10-28 2015-10-28
US201662300400P 2016-02-26 2016-02-26
US201662322906P 2016-04-15 2016-04-15

Publications (1)

Publication Number Publication Date
DOP2018000034A true DOP2018000034A (es) 2018-10-31

Family

ID=56131579

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2018000034A DOP2018000034A (es) 2015-08-06 2018-02-05 Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas

Country Status (21)

Country Link
US (2) US20170275371A1 (es)
EP (1) EP3331560A1 (es)
JP (2) JP2018525378A (es)
KR (1) KR20180032641A (es)
CN (1) CN108025073A (es)
AU (1) AU2016304401B2 (es)
BR (1) BR112018002530A2 (es)
CA (1) CA2994910A1 (es)
CL (1) CL2018000303A1 (es)
CO (1) CO2018001238A2 (es)
CR (1) CR20180080A (es)
DO (1) DOP2018000034A (es)
EA (1) EA201890457A1 (es)
HK (1) HK1249410A1 (es)
IL (1) IL257067A (es)
MA (1) MA43556A (es)
MX (1) MX2018001515A (es)
PH (1) PH12018500254A1 (es)
TW (1) TW201716084A (es)
WO (1) WO2017021791A1 (es)
ZA (1) ZA201800468B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106132439A (zh) 2014-03-31 2016-11-16 豪夫迈·罗氏有限公司 包含抗血管发生剂和ox40结合激动剂的组合疗法
EP3484518A4 (en) 2016-07-07 2020-04-22 The Board of Trustees of the Leland Stanford Junior University ANTIBODY ADJUVANT CONJUGATES
WO2019133647A1 (en) * 2017-12-29 2019-07-04 Thevax Genetics Vaccine Co., Ltd. Combination of a fusion protein vaccine with anti-ox40 antibody for use in eliciting antigen-specific immune responses
WO2020030570A1 (en) * 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
WO2020228828A1 (zh) * 2019-05-15 2020-11-19 郑州威瑞生物技术有限公司 诱导免疫细胞活性的组合物及使用该组合物治疗疾病的方法
AU2021380287A1 (en) * 2020-11-11 2023-06-22 Daiichi Sankyo Company, Limited Novel aminoalkyl glucosaminide 4-phosphate derivative

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
MXPA02011486A (es) 2000-05-19 2004-01-26 Corixa Corp Tratamiento profilactico y terapeutico de enfermedades infecciosas, autoinmunes y alergicas con compuestos a base de mono y disacarido.
EP1311522B1 (en) 2000-08-04 2006-03-22 Corixa Corporation New immunoeffector compounds
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
US6525028B1 (en) 2002-02-04 2003-02-25 Corixa Corporation Immunoeffector compounds
US6911434B2 (en) 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
US7288640B2 (en) 2002-07-08 2007-10-30 Corixa Corporation Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor
EP2572715A1 (en) * 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
NZ629913A (en) 2010-08-23 2016-01-29 Univ Texas Anti-ox40 antibodies and methods of using the same
GB201101331D0 (en) * 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
CN103946238B (zh) * 2011-08-23 2016-10-12 德克萨斯州立大学董事会 抗ox40抗体及使用其的方法
EP2659906A1 (en) * 2012-05-01 2013-11-06 Affiris AG Compositions
US20150190506A1 (en) * 2013-12-17 2015-07-09 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists

Also Published As

Publication number Publication date
CR20180080A (es) 2018-04-02
CO2018001238A2 (es) 2018-05-10
HK1249410A1 (zh) 2018-11-02
AU2016304401A1 (en) 2018-02-15
US20190338042A1 (en) 2019-11-07
JP2021121622A (ja) 2021-08-26
EA201890457A1 (ru) 2018-09-28
ZA201800468B (en) 2019-07-31
WO2017021791A1 (en) 2017-02-09
BR112018002530A2 (pt) 2018-09-25
PH12018500254A1 (en) 2018-08-13
KR20180032641A (ko) 2018-03-30
AU2016304401B2 (en) 2019-05-16
CL2018000303A1 (es) 2018-07-06
EP3331560A1 (en) 2018-06-13
MX2018001515A (es) 2018-03-15
MA43556A (fr) 2021-03-24
IL257067A (en) 2018-03-29
US20170275371A1 (en) 2017-09-28
CA2994910A1 (en) 2017-02-09
TW201716084A (zh) 2017-05-16
CN108025073A (zh) 2018-05-11
JP2018525378A (ja) 2018-09-06

Similar Documents

Publication Publication Date Title
DOP2018000034A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CL2016003056A1 (es) Dinucleótidos ciclicos moduladores de sting; composición y combinación farmacéutica que los comprende y uso de los mismos para el tratamiento de enfermedades tales como inflamación, enfermedades alérgicas y autoinmunes, enfermedades infecciosas y cancer.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CY1125205T1 (el) Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
AR106582A1 (es) Formulaciones subcutáneas de anticuerpos anti-cd38 y sus usos
GT201700167A (es) Terapias de combinación para el tratamiento de cánceres.
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
CL2016002971A1 (es) Combinación.
CL2016003260A1 (es) Profármacos de gemcitabina
CL2019001214A1 (es) Composición farmacéutica, métodos para tratamiento y sus usos.
CO2017002472A2 (es) Formulación de acetato de abiraterona
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
CL2019001996A1 (es) Usos terapéuticos de un polvo de insectos.
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
DOP2017000260A (es) Piroglutamato de vortioxetina
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CY1121105T1 (el) Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
CO2017002356A2 (es) Métodos para tratar la depresión usando moduladores de nmda
CO2018008249A2 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b
BR112017014189A2 (pt) terapia de câncer com um parvovirus combinado com bevacizumabe